Sugi Predict

Sugi Predict / Compounds / SCHEMBL1600470

SCHEMBL1600470

SCHEMBL1600470

O=S(=O)(c1ccccc1)c1[c]cccn1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 4/20 0.46
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ MET P08581 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ LOXL2 Q9Y4K0 2/20 0.38
▸ DUSP3 P51452 1/20 0.38
▸ PTPN5 P54829 1/20 0.38
▸ PTPN11 Q06124 1/20 0.38
▸ PTGS2 P35354 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ AKR1B1 P15121 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5400629 0.72 CA1 (0.36) HSD17B10
SCHEMBL1040179 0.72 LMNA (0.32) PTGS2
SCHEMBL6924070 0.71 HTR6 (0.59) HTR6KMT2AMEN1RAB9AMET
(Phenylsulfonyl)Benzene SCHEMBL25435825 0.70 HTR6 (0.93) HTR6ALDH1A1HSD17B10TDP1PKM
SCHEMBL5379893 0.69 FTO (0.38) RAB9AALDH1A1TDP1SMN1; SMN2
SCHEMBL1573626 0.68 KDM4E (0.72) HTR6KMT2AMEN1RAB9AMET
SCHEMBL315684 0.68 HTR6 (0.54) HTR6KMT2AALDH1A1HSD17B10TDP1
SCHEMBL15718171 0.68 OXTR (0.33) ALDH1A1
SCHEMBL5387264 0.68 ATM (0.36) KMT2AMEN1RAB9AALDH1A1HSD17B10
(Phenylsulfonyl)Benzene SCHEMBL11250421 0.67 HTR6 (0.88) HTR6ALDH1A1HSD17B10TDP1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104114169-A Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis ATOPIX THERAPEUTICS LTD 2014-10-22 — — CN claimed
CN-101932571-B Compounds having CRTH2 antagonist activity OXAGEN LTD 2014-04-23 — — CN claimed
US-20150246030-A1 Compounds Having CRTH2 Antagonist Activity ATOPIX THERAPEUTICS LTD (GB) 2015-09-03 — — US disclosed
US-8980927-B2 Compounds having CRTH2 antagonist activity ATOPIX THERAPEUTICS LIMITED (GB) 2015-03-17 — — US disclosed
CN-104114169-A Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis ATOPIX THERAPEUTICS LTD 2014-10-22 — — CN disclosed
CN-101932571-B Compounds having CRTH2 antagonist activity OXAGEN LTD 2014-04-23 — — CN disclosed
US-20140039012-A1 Compounds Having CRTH2 Antagonist Activity ATOPIX THERAPEUTICS LIMITED (GB) 2014-02-06 — — US disclosed
US-8563536-B2 Compounds having CRTH2 antagonist activity ATOPIX THERAPEUTICS LIMITED (GB) 2013-10-22 — — US disclosed
EP-2250161-B1 COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY ATOPIX THERAPEUTICS LTD (GB) 2013-10-16 — — EP disclosed
US-8536158-B2 Compounds having CRTH2 antagonist activity ATOPIX THERAPEUTICS LIMITED (GB) 2013-09-17 — — US disclosed
US-20110142855-A1 Compounds Having CRTH2 Antagonist Activity OXAGEN LIMITED (GB) 2011-06-16 — — US disclosed
US-7919512-B2 Compounds having CRTH2 antagonist activity OXAGEN LIMITED (GB) 2011-04-05 — — US disclosed
CN-101932571-A Compounds having crth2 antagonist activity OXAGEN LTD 2010-12-29 — — CN disclosed
EP-2250161-A1 COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY Oxagen Limited (GB) 2010-11-17 — — EP disclosed
US-20100266535-A1 Compounds Having CRTH2 Antagonist Activity OXAGEN LIMITED (GB) 2010-10-21 — — US disclosed
US-7750027-B2 Compounds having CRTH2 antagonist activity OXAGEN LIMITED (GB) 2010-07-06 — — US disclosed
US-20100063103-A1 Compounds Having CRTH2 Antagonist Activity OXAGEN LIMITED (GB) 2010-03-11 — — US disclosed
CN-101568523-A For preparing {2- [1- (3) LILLY CO ELI (US) 2009-10-28 — — CN disclosed
WO-2009090414-A1 COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY OXAGEN LIMITED (GB) 2009-07-23 — — WO disclosed
US-20090186923-A1 Compounds Having CRTH2 Antagonist Activity OXAGEN LIMITED (GB) 2009-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110142855-A1 Compounds Having CRTH2 Antagonist Activity HRH2, NR3C2, HRH4 HTR6 653/4885KMT2A 2453/4885MEN1 2925/4885
US-20140039012-A1 Compounds Having CRTH2 Antagonist Activity NR3C2, HRH2, NR2C2 HTR6 641/4885KMT2A 2397/4885MEN1 2985/4885
US-20100266535-A1 Compounds Having CRTH2 Antagonist Activity NR3C2, HRH2, NR2C2 HTR6 641/4885KMT2A 2397/4885MEN1 2985/4885
US-20090186923-A1 Compounds Having CRTH2 Antagonist Activity HRH2, HRH4, NR2C2 HTR6 822/4885KMT2A 3327/4885MEN1 4692/4885
US-20150246030-A1 Compounds Having CRTH2 Antagonist Activity NR3C2, HRH2, NR2C2 HTR6 645/4885KMT2A 2374/4885MEN1 2983/4885
US-20100063103-A1 Compounds Having CRTH2 Antagonist Activity HRH2, NR3C2, HRH4 HTR6 653/4885KMT2A 2453/4885MEN1 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.